ridaforolimus

also known as MK8669 · AP23573 · deforolimus

Small molecule targets MTOR via inhibition

Developed for: cancer · endometrial cancer · breast cancer · cancer of unknown primary site · lymphoma · neoplasm · non-small cell lung carcinoma · plasma cell myeloma
+15 more
· prostate cancer · sarcoma · soft tissue sarcoma · bone sarcoma · breast neoplasm · coronary stenosis · gliosarcoma · leiomyosarcoma · leukemia · liposarcoma · metastatic neoplasm · myelodysplastic syndrome · osteosarcoma · ovarian cancer · refractory malignant neoplasm
Investigated by: Merck Sharp & Dohme LLC · Ariad Pharmaceuticals · H. Lee Moffitt Cancer Center and Research Institute · Angela Taber MD · Fox Chase Cancer Center · Johns Hopkins All Children's Hospital
+11 more
· Medinol Ltd. · Memorial Hospital of Rhode Island · Memorial Sloan Kettering Cancer Center · NCIC Clinical Trials Group · National Cancer Institute (NCI) · Pediatric Cancer Foundation · Rhode Island Hospital · Roger Williams Medical Center · The Miriam Hospital · The University of Texas Health Science Center at San Antonio · University of Colorado, Denver

Trials 37 · a red edge is where a trial was stopped

today NCT03702608 · not/applicable NCT01605396 · Ph 2 NCT01431547 · Ph 1 NCT01431534 · Ph 1 NCT01380184 · Ph 1 NCT01256268 · Ph 1 NCT01295632 · Ph 1 NCT01296659 · Ph 1 NCT01243762 · Ph 1 NCT01169532 · Ph 1 NCT01234857 · Ph 2 NCT01212627 · Ph 1 NCT01220570 · Ph 1 NCT01071304 · Ph 1 NCT01043887 · Ph 1 NCT01010672 · Ph 2 NCT00874731 · Ph 1 NCT00818675 · Ph 2 NCT00836927 · Ph 2 NCT00770185 · Ph 2 NCT00777959 · Ph 2 NCT00781846 · Ph 1 NCT00739830 · Ph 2 NCT00730379 · Ph 1 NCT00736970 · Ph 2 NCT00694083 · Ph 1 NCT00704054 · Ph 1 NCT00538239 · Ph 3 NCT00288431 · Ph 1 NCT00122343 · Ph 2 NCT00112372 · Ph 1 NCT00110188 · Ph 2 NCT00093080 · Ph 2 NCT00087451 · Ph 1 NCT00086125 · Ph 2 NCT00060645 · Ph 1 NCT00060632 · Ph 1

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 122 trials
Phase 1	NCT01431547	Feb 2012 → Sep 2013	cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01431534	Jan 2012 → Aug 2013	cancer	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 1	NCT01380184	Jul → Oct 2011	cancer of unknown primary site	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01256268	Jun 2011 → Feb 2016	endometrial cancer, ovarian cancer	H. Lee Moffitt Cancer Center and Research Institute	Completed	No outcome recorded
Phase 1	NCT01295632	Feb 2011 → Dec 2013	cancer of unknown primary site	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01296659	Feb → Aug 2011	soft tissue sarcoma	The University of Texas Health Science Center at San Antonio	Withdrawn	No outcome recorded
Phase 1	NCT01243762	Nov 2010 → Dec 2012	cancer	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 1	NCT01169532	Oct 2010 → Mar 2014	cancer of unknown primary site, lymphoma	Fox Chase Cancer Center	Completed	No outcome recorded
Phase 1	NCT01212627	Sep 2010 → Dec 2012	non-small cell lung carcinoma	Angela Taber MD	Terminated	No outcome recorded
Phase 1	NCT01220570	Sep 2010 → Dec 2012	breast cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01071304	Mar → Sep 2010	refractory malignant neoplasm	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01043887	Jan → Apr 2010	liver disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00874731	Apr → Oct 2009	metastatic malignant neoplasm	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00781846	Oct 2008 → Feb 2010	cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00730379	Jul 2008 → Nov 2010	neoplasm	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00694083	Jun 2008 → Sep 2009	neoplasm	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00704054	Jan 2008 → Jun 2010	cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00288431	Feb 2006 → Jul 2008	sarcoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00112372	May 2005 → Dec 2008	cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00087451	Jul 2004 → Nov 2005	gliosarcoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00060645	May 2003 → May 2006	plasma cell myeloma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00060632	Apr 2003 → Oct 2005	plasma cell myeloma	Merck Sharp & Dohme LLC	Completed	No outcome recorded

Phase 213 trials
Phase 2	NCT01605396	Jul 2012 → Feb 2014	breast neoplasm	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT01234857	Sep 2010 → Oct 2013	breast cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT01010672	Nov 2009 → Sep 2011	sarcoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00818675	Mar 2009 → Aug 2012	non-small cell lung carcinoma	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 2	NCT00836927	Feb 2009 → Apr 2017	—	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 2	NCT00770185	Nov 2008 → Mar 2012	endometrial cancer	NCIC Clinical Trials Group	Completed	No outcome recorded
Phase 2	NCT00777959	Oct 2008 → May 2011	prostate cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00739830	Aug 2008 → Feb 2011	endometrial cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00736970	Jul 2008 → Jan 2011	breast cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00122343	Aug 2005 → Jan 2008	endometrial cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00110188	May 2005 → Apr 2007	prostate cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00093080	Oct 2004 → Nov 2008	leiomyosarcoma, liposarcoma, metastatic neoplasm, osteosarcoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00086125	Jun 2004 → Jun 2006	leukemia, lymphoma, myelodysplastic syndrome	Merck Sharp & Dohme LLC	Completed	No outcome recorded

Phase 31 trial
Phase 3	NCT00538239	Oct 2007 → Oct 2010	bone sarcoma, soft tissue sarcoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase not applicable1 trial
—	NCT03702608	Nov 2018 → Mar 2019	coronary stenosis	Medinol Ltd.	Completed	No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 38 sources stand behind the page.

Field	Value	Cited text
Known as	ridaforolimus	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00093080 ↗ 35 NCT00736970 ↗ NCT00288431 ↗ NCT00122343 ↗ NCT01256268 ↗ NCT01431534 ↗ NCT00730379 ↗ NCT00110188 ↗ NCT01431547 ↗ NCT00874731 ↗ NCT00739830 ↗ NCT00060645 ↗ NCT00086125 ↗ NCT01010672 ↗ NCT01234857 ↗ NCT01071304 ↗ NCT00836927 ↗ NCT01605396 ↗ NCT00781846 ↗ NCT01212627 ↗ NCT01296659 ↗ NCT00060632 ↗ NCT01220570 ↗ NCT01295632 ↗ NCT00704054 ↗ NCT00777959 ↗ NCT01169532 ↗ NCT00538239 ↗ NCT01043887 ↗ NCT00818675 ↗ NCT01243762 ↗ NCT01380184 ↗ NCT00694083 ↗ NCT00770185 ↗ NCT00112372 ↗ NCT03702608 ↗
Known as	AP23573	“A Study to Evaluate the Effect of Multiple Doses of Ridaforolimus (AP23573; MK-8669) on the Single Dose Pharmacokinetics of Midazolam.” NCT01071304 ↗ 3 “Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)” NCT00110188 ↗ “Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009” NCT00730379 ↗ NCT00087451 ↗
Known as	deforolimus	“Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009.” NCT00777959 ↗ 3 “Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009” NCT00730379 ↗ “ridaforolimus was also known as deforolimus until May 2009” NCT00110188 ↗ “ridaforolimus was also known as deforolimus until May 2009” NCT00836927 ↗
Known as	MK8669	“Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks” NCT01220570 ↗ 4 “A Study to Evaluate the Effect of Multiple Doses of Ridaforolimus (AP23573; MK-8669) on the Single Dose Pharmacokinetics of Midazolam.” NCT01071304 ↗ “Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)” NCT00110188 ↗ “Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009” NCT00730379 ↗ “ridaforolimus (MK8669)” NCT00777959 ↗
Action	Inhibit	“an mTOR Inhibitor” NCT00060632 ↗
Modality	Small molecule	— CHEMBL2103839 ↗
Route	Intravenous	“by intravenous infusion” NCT00060632 ↗
Target	MTOR	“an mTOR Inhibitor” NCT00060632 ↗